{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:12:23Z","timestamp":1791821543585,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003670","name":"National Evidence-based Healthcare Collaborating Agency","doi-asserted-by":"publisher","award":["NA17-004"],"award-info":[{"award-number":["NA17-004"]}],"id":[{"id":"10.13039\/501100003670","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) are more likely to receive long-term therapy with proton pump inhibitors (PPIs). This study aimed to investigate the risk of osteoporotic fractures in PPI users compared to histamine-2 receptor antagonist (H2RA) users and the association between fractures and the duration and regular use of PPI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A population-based, nationwide nested case-control study from January 2006 to December 2015 was performed using Korean National Health Insurance Service claims data. We included patients \u226550\u2009years of age, without previous fractures, newly prescribed with PPI or H2RA, and diagnosed with PUD or GERD from 2006 to 2015. Patients with osteoporotic fracture (<jats:italic>n<\/jats:italic>\u2009=\u200959,240) were matched with the non-fracture control group (<jats:italic>n<\/jats:italic>\u2009=\u2009296,200) at a 1:5 ratio based on sex, age, cohort entry date, follow-up duration, and bisphosphonate use. The osteoporotic fractures were defined using the diagnostic codes of claims data (M80, M81, M82, M484, M485, S220, S221, S320, S327, S422, S423, S525, S526, S72).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The higher the cumulative use of PPIs, the higher the osteoporotic fracture risk (<jats:italic>P<\/jats:italic> for trend &lt;\u20090.001). The risk of osteoporotic fracture in the patients whose cumulative use of PPI was more than 1\u2009year was higher than that of others (OR: 1.42, 95% CI: 1.32\u20131.52). Patients who regularly used PPI in the recent 1\u2009year had a higher risk of osteoporotic fracture than exclusive H2RA users (OR: 1.37, 95% CI: 1.26\u20131.50).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The risk of osteoporotic fracture increased with the duration of PPI use, especially when PPI was used for \u22651\u2009year and regularly in the recent 1\u2009year.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12877-020-01794-3","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T20:02:46Z","timestamp":1602792166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease"],"prefix":"10.1186","volume":"20","author":[{"given":"Joo-Hyun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Yeon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hyung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungdo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7421-4501","authenticated-orcid":false,"given":"Do-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinnie","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"issue":"10","key":"1794_CR1","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/pds.1969","volume":"19","author":"S Hollingworth","year":"2010","unstructured":"Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf. 2010;19(10):1019\u201324.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"17","key":"1794_CR2","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","volume":"314","author":"ED Kantor","year":"2015","unstructured":"Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015;314(17):1818\u201330.","journal-title":"JAMA"},{"issue":"7","key":"1794_CR3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/jgh.13737","volume":"32","author":"LH Eusebi","year":"2017","unstructured":"Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, Bazzoli F. Proton pump inhibitors: risks of long-term use. J Gastroenterol Hepatol. 2017;32(7):1295\u2013302.","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"1794_CR4","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00296-018-4142-x","volume":"38","author":"S Hussain","year":"2018","unstructured":"Hussain S, Siddiqui AN, Habib A, Hussain MS, Najmi AK. Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis. Rheumatol Int. 2018;38(11):1999\u20132014.","journal-title":"Rheumatol Int"},{"issue":"24","key":"1794_CR5","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","volume":"296","author":"YX Yang","year":"2006","unstructured":"Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947\u201353.","journal-title":"JAMA"},{"issue":"1","key":"1794_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1053\/j.gastro.2010.03.055","volume":"139","author":"DA Corley","year":"2010","unstructured":"Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93\u2013101.","journal-title":"Gastroenterology"},{"issue":"11","key":"1794_CR7","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1002\/jbmr.2279","volume":"29","author":"JR Lewis","year":"2014","unstructured":"Lewis JR, Barre D, Zhu K, Ivey KL, Lim EM, Hughes J, Prince RL. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res. 2014;29(11):2489\u201397.","journal-title":"J Bone Miner Res"},{"key":"1794_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.bone.2015.08.024","volume":"81","author":"MMC van der Hoorn","year":"2015","unstructured":"van der Hoorn MMC, Tett SE, de Vries OJ, Dobson AJ, Peeters G. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: a prospective cohort study. Bone. 2015;81:675\u201382.","journal-title":"Bone"},{"issue":"12","key":"1794_CR9","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726\u201333.","journal-title":"Osteoporos Int"},{"issue":"6","key":"1794_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1359\/jbmr.070315","volume":"22","author":"ND Nguyen","year":"2007","unstructured":"Nguyen ND, Ahlborg HG, Center JR, Eisman JA, Nguyen TV. Residual lifetime risk of fractures in women and men. J Bone Miner Res. 2007;22(6):781\u20138.","journal-title":"J Bone Miner Res"},{"issue":"10","key":"1794_CR11","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1046\/j.1532-5415.2002.50455.x","volume":"50","author":"CL Leibson","year":"2002","unstructured":"Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc. 2002;50(10):1644\u201350.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"1794_CR12","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1001\/archinte.1991.00400100100017","volume":"151","author":"EA Chrischilles","year":"1991","unstructured":"Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med. 1991;151(10):2026\u201332.","journal-title":"Arch Intern Med"},{"issue":"8","key":"1794_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s001980200084","volume":"13","author":"TP van Staa","year":"2002","unstructured":"van Staa TP, Leufkens HG, Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int. 2002;13(8):624\u20139.","journal-title":"Osteoporos Int"},{"issue":"5","key":"1794_CR14","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s001980070115","volume":"11","author":"AG Randell","year":"2000","unstructured":"Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA. Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int. 2000;11(5):460\u20136.","journal-title":"Osteoporos Int"},{"issue":"2","key":"1794_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00223-006-0021-7","volume":"79","author":"P Vestergaard","year":"2006","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79(2):76\u201383.","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"1794_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00223-008-9188-4","volume":"84","author":"C Roux","year":"2009","unstructured":"Roux C, Briot K, Gossec L, Kolta S, Blenk T, Felsenberg D, Reid DM, Eastell R, Gluer CC. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int. 2009;84(1):13\u20139.","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"1794_CR17","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00198-012-2112-9","volume":"24","author":"LA Fraser","year":"2013","unstructured":"Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD, CaMos Research G. The effect of proton pump inhibitors on fracture risk: report from the Canadian multicenter osteoporosis study. Osteoporos Int. 2013;24(4):1161\u20138.","journal-title":"Osteoporos Int"},{"issue":"2","key":"1794_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.bone.2012.09.028","volume":"52","author":"C Reyes","year":"2013","unstructured":"Reyes C, Formiga F, Coderch M, Hoyo J, Ferriz G, Casanovas J, Monteserin R, Brotons C, Rojas M, Moral I. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone. 2013;52(2):557\u201361.","journal-title":"Bone"},{"issue":"4","key":"1794_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.maturitas.2014.05.019","volume":"78","author":"LM Moberg","year":"2014","unstructured":"Moberg LM, Nilsson PM, Samsioe G, Borgfeldt C. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas. 2014;78(4):310\u20135.","journal-title":"Maturitas"},{"issue":"6","key":"1794_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00223-014-9855-6","volume":"94","author":"J Ding","year":"2014","unstructured":"Ding J, Heller DA, Ahern FM, Brown TV. The relationship between proton pump inhibitor adherence and fracture risk in the elderly. Calcif Tissue Int. 2014;94(6):597\u2013607.","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"1794_CR21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.annepidem.2014.01.004","volume":"24","author":"AL Adams","year":"2014","unstructured":"Adams AL, Black MH, Zhang JL, Shi JM, Jacobsen SJ. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study. Ann Epidemiol. 2014;24(4):286\u201390.","journal-title":"Ann Epidemiol"},{"issue":"8","key":"1794_CR22","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1592\/phco.28.8.951","volume":"28","author":"JA Kaye","year":"2008","unstructured":"Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28(8):951\u20139.","journal-title":"Pharmacotherapy"},{"issue":"9","key":"1794_CR23","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1007\/s00535-012-0722-9","volume":"48","author":"J Lee","year":"2013","unstructured":"Lee J, Youn K, Choi NK, Lee JH, Kang D, Song HJ, Park BJ. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol. 2013;48(9):1016\u201322.","journal-title":"J Gastroenterol"},{"issue":"12","key":"1794_CR24","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/jbmr.3842","volume":"34","author":"M Fusaro","year":"2019","unstructured":"Fusaro M, D'Arrigo G, Pitino A, Iervasi G, Tentori F, Robinson B, Aghi A, Bieber B, McCullogh K, Fabris F, et al. Increased risk of bone fractures in hemodialysis patients treated with proton pump inhibitors in real world: results from the Dialysis outcomes and practice patterns study (DOPPS). J Bone Miner Res. 2019;34(12):2238\u201345.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1794_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00223-008-9170-1","volume":"83","author":"EW Yu","year":"2008","unstructured":"Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, Bauer DC. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83(4):251\u20139.","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"1794_CR26","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/archinternmed.2010.94","volume":"170","author":"SL Gray","year":"2010","unstructured":"Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2010;170(9):765\u201371.","journal-title":"Arch Intern Med"},{"issue":"3","key":"1794_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00198-010-1337-8","volume":"22","author":"S Pouwels","year":"2011","unstructured":"Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG, de Boer A, van Staa T, de Vries F. Use of proton pump inhibitors and risk of hip\/femur fracture: a population-based case-control study. Osteoporos Int. 2011;22(3):903\u201310.","journal-title":"Osteoporos Int"},{"issue":"6","key":"1794_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/phar.1410","volume":"34","author":"L Cea Soriano","year":"2014","unstructured":"Cea Soriano L, Ruigomez A, Johansson S, Garcia Rodriguez LA. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting. Pharmacotherapy. 2014;34(6):570\u201381.","journal-title":"Pharmacotherapy"},{"issue":"9","key":"1794_CR29","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/j.1365-2036.2005.02441.x","volume":"21","author":"GI Leontiadis","year":"2005","unstructured":"Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia--a post hoc analysis from the Cochrane collaboration. Aliment Pharmacol Ther. 2005;21(9):1055\u201361.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1794_CR30","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s00198-011-1685-z","volume":"23","author":"JH Park","year":"2012","unstructured":"Park JH, Song YM, Sung J, Lee K, Kim YS, Park YS. Genetic influence on bone mineral density in Korean twins and families: the healthy twin study. Osteoporos Int. 2012;23(4):1343\u20139.","journal-title":"Osteoporos Int"},{"issue":"4","key":"1794_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1503\/cmaj.071330","volume":"179","author":"LE Targownik","year":"2008","unstructured":"Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319\u201326.","journal-title":"CMAJ"},{"issue":"11","key":"1794_CR32","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/pds.2026","volume":"19","author":"HF Chiu","year":"2010","unstructured":"Chiu HF, Huang YW, Chang CC, Yang CY. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2010;19(11):1131\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1794_CR33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2036.1992.tb00553.x","volume":"6","author":"H Koop","year":"1992","unstructured":"Koop H. Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther. 1992;6(4):399\u2013406.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1794_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.maturitas.2009.07.006","volume":"64","author":"MR Fournier","year":"2009","unstructured":"Fournier MR, Targownik LE, Leslie WD. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas. 2009;64(1):9\u201313.","journal-title":"Maturitas"},{"key":"1794_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/00365529109111222","volume":"188","author":"HP Festen","year":"1991","unstructured":"Festen HP. Intrinsic factor secretion and cobalamin absorption. Physiology and pathophysiology in the gastrointestinal tract. Scand J Gastroenterol Suppl. 1991;188:1\u20137.","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"1","key":"1794_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00004836-200001000-00006","volume":"30","author":"CW Howden","year":"2000","unstructured":"Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol. 2000;30(1):29\u201333.","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"1794_CR37","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1053\/j.gastro.2010.08.023","volume":"139","author":"YX Yang","year":"2010","unstructured":"Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139(4):1115\u201327.","journal-title":"Gastroenterology"},{"issue":"3","key":"1794_CR38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3390\/nu2030299","volume":"2","author":"F O'Leary","year":"2010","unstructured":"O'Leary F, Samman S. Vitamin B12 in health and disease. Nutrients. 2010;2(3):299\u2013316.","journal-title":"Nutrients"},{"issue":"2","key":"1794_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1056\/NEJMcp1113996","volume":"368","author":"SP Stabler","year":"2013","unstructured":"Stabler SP. Clinical practice. Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149\u201360.","journal-title":"N Engl J Med"},{"issue":"6","key":"1794_CR40","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3109\/00365529409092460","volume":"29","author":"R Gagnemo-Persson","year":"1994","unstructured":"Gagnemo-Persson R, H\u00e5kanson R, Sundler F, Persson P. Growth of the parathyroid glands in omeprazole-treated chickens. Scand J Gastroenterol. 1994;29(6):493\u20137.","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"1794_CR41","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s002239900325","volume":"61","author":"R Gagnemo-Persson","year":"1997","unstructured":"Gagnemo-Persson R, Samuelsson A, H\u00e2kanson R, Persson P. Chicken parathyroid hormone gene expression in response to gastrin, omeprazole, ergocalciferol, and restricted food intake. Calcif Tissue Int. 1997;61(3):210\u20135.","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"1794_CR42","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1001\/jamainternmed.2016.1845","volume":"176","author":"M Fusaro","year":"2016","unstructured":"Fusaro M, Giannini S, Gallieni M. Adverse effects of proton pump inhibitors in chronic kidney disease. JAMA Intern Med. 2016;176(6):866.","journal-title":"JAMA Intern Med"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-020-01794-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-020-01794-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-020-01794-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T14:37:56Z","timestamp":1634308676000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-020-01794-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1794"],"URL":"https:\/\/doi.org\/10.1186\/s12877-020-01794-3","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"21 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All research procedures and ethical aspects were approved by the Institutional Review Board of the National Evidence-based Healthcare Collaborating Agency (approval no. 17\u2013011). Informed consent was waived by the IRB because the KNHIS dataset was constructed after anonymization, based on the strict confidentiality guidelines of the Korean Government.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"407"}}